These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 19280405)

  • 1. Which factors hinder the decision of Polish HIV-positive patients to take up antiretroviral therapy?
    Rogowska-Szadkowska D; Chlabicz S; Oltarzewska MA; Sawicka-Powierza J
    AIDS Care; 2009 Mar; 21(3):280-3. PubMed ID: 19280405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The decision to forgo antiretroviral therapy in people living with HIV compliance as paternalism or partnership?
    Kremer H; Bader A; O'Cleirigh C; Bierhoff HW; Brockmeyer NH
    Eur J Med Res; 2004 Feb; 9(2):61-70. PubMed ID: 15090291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of the Millon Behavioral Medicine Diagnostic (MBMD) to predict adherence to highly active antiretroviral therapy (HAART) medication regimens among HIV-positive men and women.
    Cruess DG; Minor S; Antoni MH; Millon T
    J Pers Assess; 2007 Dec; 89(3):277-90. PubMed ID: 18001228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reasons for unsatisfactory acceptance of antiretroviral treatment in the urban Kibera slum, Kenya.
    Unge C; Johansson A; Zachariah R; Some D; Van Engelgem I; Ekstrom AM
    AIDS Care; 2008 Feb; 20(2):146-9. PubMed ID: 18293122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA.
    Murphy DA; Wilson CM; Durako SJ; Muenz LR; Belzer M;
    AIDS Care; 2001 Feb; 13(1):27-40. PubMed ID: 11177463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients and family care givers' experiences around highly active antiretroviral therapy (HAART).
    Sacajiu G; Raveis VH; Selwyn P
    AIDS Care; 2009 Dec; 21(12):1528-36. PubMed ID: 20024732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perceptions of HAART among gay men who declined a treatment offer: preliminary results from an interview-based study.
    Cooper V; Buick D; Horne R; Lambert N; Gellaitry G; Leake H; Fisher M
    AIDS Care; 2002 Jun; 14(3):319-28. PubMed ID: 12042077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV/AIDS patient involvement in antiretroviral treatment decisions.
    Marelich WD; Johnston Roberts K; Murphy DA; Callari T
    AIDS Care; 2002 Feb; 14(1):17-26. PubMed ID: 11798402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "I will start treatment when I think the time is right": HIV-positive gay men talk about their decision not to access antiretroviral therapy.
    Gold RS; Ridge DT
    AIDS Care; 2001 Dec; 13(6):693-708. PubMed ID: 11720640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.
    Sabundayo BP; McArthur JH; Langan SJ; Gallant JE; Margolick JB
    Pharmacotherapy; 2006 May; 26(5):674-81. PubMed ID: 16637796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the prevalence of distal symmetrical polyneuropathy and its risk factors among HAART-treated and untreated HIV infected individuals.
    Shurie JS; Deribew A
    Ethiop Med J; 2010 Apr; 48(2):85-93. PubMed ID: 20608012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study.
    Small W; Wood E; Betteridge G; Montaner J; Kerr T
    AIDS Care; 2009 Jun; 21(6):708-14. PubMed ID: 19806487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Simply forgot' is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence.
    Barfod TS; Sørensen HT; Nielsen H; Rodkjaer L; Obel N
    HIV Med; 2006 Jul; 7(5):285-90. PubMed ID: 16945072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.
    van Lunzen J; Liess H; Arastéh K; Walli R; Daut B; Schürmann D
    HIV Med; 2007 May; 8(4):220-5. PubMed ID: 17461849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors.
    Carbonara S; Fiorentino G; Serio G; Maggi P; Ingravallo G; Monno L; Bruno F; Coppola S; Pastore G; Angarano G
    J Infect; 2001 May; 42(4):251-6. PubMed ID: 11545567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.